Page 2 - நுண்ணுயிரியல் சீன கலைக்கழகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நுண்ணுயிரியல் சீன கலைக்கழகம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நுண்ணுயிரியல் சீன கலைக்கழகம் Today - Breaking & Trending Today

Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

(1)
SHANGHAI, China, July 30, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted its supplemental New Drug Application (sNDA) for toripalimab in combination with platinum-containing chemotherapy as the first-line treatment for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC). It is the fifth NDA submitted for toripalimab in China.
The supplemental NDA is based on the JUPITER-06 study (Clinicaltrials.gov identifier: NCT03829969), which is a randomized, double-blind, placebo-controlled Phase III clinical study led by Professor Ruihua Xu from Sun Yat-sen University Cancer Center. A total of 514 patients were enrolled. The co-primary endpoints were progression-free survival (PFS) as assessed by ....

United States , Ruihua Xu , Patricia Keegan , Junshi Biosciences , Zhi Li , Eli Lilly , Institute Of Microbiology Chinese Academy Science , Ir Team , Drug Administration , Data Monitoring Committee , Sun Yat Sen University Cancer Center , National Reimbursement Drug List , National Medical Products Administration , Pr Team , New Drug Application , Sun Yat Sen University Cancer , Blinded Independent Review Committee , Independent Data Monitoring Committee , For Global , Chief Medical Officer , National Reimbursement Drug , Breakthrough Therapy Designation , Chinese Society , Clinical Oncology , Neck Tumors , Urothelial Carcinoma ,

Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for .
Junshi BiosciencesJuly 30, 2021 GMT
SHANGHAI, China, July 30, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted its supplemental New Drug Application (sNDA) for toripalimab in combination with platinum-containing chemotherapy as the first-line treatment for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC). It is the fifth NDA submitted for toripalimab in China. ....

United States , San Francisco , Ruihua Xu , Patricia Keegan , Junshi Biosciences , Zhi Li , Eli Lilly , Institute Of Microbiology Chinese Academy Science , Ir Team , Drug Administration , Data Monitoring Committee , Sun Yat Sen University Cancer Center , National Reimbursement Drug List , National Medical Products Administration , Pr Team , New Drug Application , Sun Yat Sen University Cancer , Blinded Independent Review Committee , Independent Data Monitoring Committee , For Global , Chief Medical Officer , National Reimbursement Drug , Breakthrough Therapy Designation , Chinese Society , Clinical Oncology , Neck Tumors ,

Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines | Comunicados | Edición USA

20 jul 2021
Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines
SHANGHAI, China, July 20, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the process development and optimization of mRNA and delivery vehicles and the research and development of new nucleic acid drugs, to develop and commercialize new drugs for the global market in the fields of cancer, infectious diseases, rare diseases, and other diseases, based on the mRNA technology and other technology platforms. ....

United States , San Francisco , Zihao Wang , Junshi Bioscience , Junshi Biosciences , Eli Lilly , Institute Of Microbiology Chinese Academy Science , Ir Team , Pr Team , Rna Technology Platform , Announce Joint Venture , Develop Innovative Self Replicating , Chief Executive Officer , Microbiology Chinese Academy , Emergency Use Authorization , ஒன்றுபட்டது மாநிலங்களில் , சான் பிரான்சிஸ்கோ , எலி லில்லி , நிறுவனம் ஆஃப் நுண்ணுயிரியல் சீன கலைக்கழகம் அறிவியல் , ஈர் அணி , ப்ர் அணி , தலைமை நிர்வாகி அதிகாரி , நுண்ணுயிரியல் சீன கலைக்கழகம் , அவசரம் பயன்பாடு அங்கீகாரம் ,

Junshi Biosciences and Immorna Announce Joint Venture to

Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines
July 19, 2021 20:41 ET
| Source:
Junshi Biosciences
Junshi Biosciences
Shanghai, CHINA
SHANGHAI, China, July 20, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the process development and optimization of mRNA and delivery vehicles and the research and development of new nucleic acid drugs, to develop and commercialize new drugs for the global market in the fields of cancer, infectious diseases, rare diseases, and other diseases, based on the mRNA technology and other technology platform ....

United States , San Francisco , Zihao Wang , Junshi Bioscience , Junshi Biosciences , Eli Lilly , Institute Of Microbiology Chinese Academy Science , Ir Team , Pr Team , Rna Technology Platform , Chief Executive Officer , Microbiology Chinese Academy , Emergency Use Authorization , ஒன்றுபட்டது மாநிலங்களில் , சான் பிரான்சிஸ்கோ , எலி லில்லி , நிறுவனம் ஆஃப் நுண்ணுயிரியல் சீன கலைக்கழகம் அறிவியல் , ஈர் அணி , ப்ர் அணி , தலைமை நிர்வாகி அதிகாரி , நுண்ணுயிரியல் சீன கலைக்கழகம் , அவசரம் பயன்பாடு அங்கீகாரம் ,

Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating .
Junshi BiosciencesJuly 20, 2021 GMT
SHANGHAI, China, July 20, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the process development and optimization of mRNA and delivery vehicles and the research and development of new nucleic acid drugs, to develop and commercialize new drugs for the global market in the fields of cancer, infectious diseases, rare diseases, and other diseases, based on the mRNA technology and other technology platforms. ....

United States , San Francisco , Zihao Wang , Junshi Bioscience , Junshi Biosciences , Eli Lilly , Institute Of Microbiology Chinese Academy Science , Ir Team , Pr Team , Rna Technology Platform , Chief Executive Officer , Microbiology Chinese Academy , Emergency Use Authorization , ஒன்றுபட்டது மாநிலங்களில் , சான் பிரான்சிஸ்கோ , எலி லில்லி , நிறுவனம் ஆஃப் நுண்ணுயிரியல் சீன கலைக்கழகம் அறிவியல் , ஈர் அணி , ப்ர் அணி , தலைமை நிர்வாகி அதிகாரி , நுண்ணுயிரியல் சீன கலைக்கழகம் , அவசரம் பயன்பாடு அங்கீகாரம் ,